---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-036500"
form_type: "8-K"
ticker: "ANEB"
cik: "0001815974"
company_name: "Anebulo Pharmaceuticals, Inc."
filed_at: "2023-10-06T23:59:59+00:00"
generated_at: "2026-06-10T03:34:36.086202+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Anebulo terminates CEO Simon Allen, appoints Richie Cunningham as new CEO

## Summary
- Simon Allen terminated without cause as CEO; resigned from board effective Oct 5, 2023.
- Richie Cunningham appointed CEO and board member; previously CEO of Tyme Technologies and IXC Discovery.
- Cunningham receives $450k base salary, time-vesting option for 600k shares (16 quarterly installments), and performance-based option for 140k shares.
- Bimal Shah appointed to board and to Audit and Compensation Committees.

## SEC filing metadata
- accession: 0001493152-23-036500
- form_type: 8-K
- ticker: ANEB
- cik: 0001815974
- company_name: Anebulo Pharmaceuticals, Inc.
- filed_at: 2023-10-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815974/000149315223036500/0001493152-23-036500-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815974/000149315223036500/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-036500
- JSON: https://secwatch.observer/filing/0001493152-23-036500.json
- Plain text: https://secwatch.observer/filing/0001493152-23-036500.txt

## Key facts
- Executive change
  Simon Allen departed as Chief Executive Officer at Anebulo Pharmaceuticals, Inc..
  - Action: terminated without cause
  - Role: Chief Executive Officer
  source text: On October 6, 2023, Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), terminated without cause the employment of Simon Allen, the Company’s Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815974/000149315223036500/0001493152-23-036500-index.htm
- Executive change
  Bimal Shah was appointed as Director at Anebulo Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Director
  source text: the Company appointed Bimal Shah as a member of the Board and as a member of the Audit Committee and the Compensation Committee of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815974/000149315223036500/0001493152-23-036500-index.htm
- Executive change
  Richard (Richie) Anthony Cunningham was appointed as Chief Executive Officer at Anebulo Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: the Board appointed Richard (Richie) Anthony Cunningham as the Company’s Chief Executive Officer and as a member of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815974/000149315223036500/0001493152-23-036500-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.